Aducanumab (Aduhelm) is Considered Experimental and Investigational

After reviewing the clinical data that is available on the efficacy and safety of the Alzheimer’s drug aducanumab (Aduhelm), Harvard Pilgrim Health Care has concluded that it is experimental and investigational.

In making this clinical determination, we consulted with our internal resources, as well as our regional providers who offer extensive expertise in this area. This decision was made with our members’ health and well-being in mind and was not based on cost. Our priority is to provide our members with coverage for effective and safe treatments that are based on scientific evidence.

Alzheimer’s disease is very personal to many of us at Harvard Pilgrim Health Care, and the need for an effective new treatment for Alzheimer’s is indisputable. We are encouraged that there is a robust pipeline of other Alzheimer’s drugs in current research and development.

As further studies and data related to aducanumab become available, we will carefully review the information and continue to evaluate this clinical decision.

While our clinical evaluation of this drug therapy is universal, for our Medicare and Medicaid lines of business we will continue to follow the direction of our federal and state regulators regarding coverage.

Publication Information

Annmarie Dadoly,
Editor

Joseph O’Riordan,
Writer

Kristin Edmonston,
Production Coordinator